Lipocine (LPCN) News Today $4.60 +0.23 (+5.26%) As of 03:50 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Lipocine Updates Corporate Presentation, Files 8-K with SECJanuary 21 at 2:05 AM | americanbankingnews.comLipocine (NASDAQ:LPCN) Research Coverage Started at StockNews.comJanuary 20 at 1:17 AM | americanbankingnews.comStockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)January 11, 2025 | americanbankingnews.comLa FDA accélère le traitement de la sarcopénie de LipocineDecember 17, 2024 | fr.investing.comLipocine Inc.: FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated CirrhosisDecember 17, 2024 | finanznachrichten.deLipocine's LPCN 1148 Gets Fast Track Status To Treat Sarcopenia In Decompensated Cirrhosis PatientsDecember 17, 2024 | markets.businessinsider.comFDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated CirrhosisDecember 17, 2024 | prnewswire.comLipocine announces publication, discussion of LPCN 1148November 19, 2024 | markets.businessinsider.comLipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut SessionNovember 18, 2024 | prnewswire.comLipocine Announces Financial Results for the Third Quarter Ended September 30, 2024November 7, 2024 | prnewswire.comLipocine conclut un accord pour commercialiser TLANDO en Corée du SudOctober 31, 2024 | fr.investing.comLipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South KoreaOctober 31, 2024 | prnewswire.comLipocine annonce des résultats prometteurs pour l'étude sur la brexanolone oraleOctober 12, 2024 | fr.investing.comLipocine Announces Positive Oral Brexanolone Quantitative EEG ResultsOctober 10, 2024 | prnewswire.comLipocine signs supply and distribution agreement with Pharmalink for TlandoOctober 10, 2024 | finance.yahoo.comLipocine Inks Distribution Deal With Pharmalink To Commercialize TLANDO In GCC CountriesOctober 8, 2024 | markets.businessinsider.comLipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) CountriesOctober 8, 2024 | prnewswire.comLipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024October 2, 2024 | prnewswire.comLipocine to Present at H.C. Wainwright 8th Annual MASH Investor ConferenceSeptember 30, 2024 | prnewswire.comAlliance Global Partners Initiates Coverage of Lipocine (LPCN) with Buy RecommendationSeptember 26, 2024 | msn.comLipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®September 5, 2024 | prnewswire.comLipocine to Present at H.C. Wainwright 26th Annual Global Investment ConferenceAugust 27, 2024 | prnewswire.comLipocine Announces Financial Results for the Second Quarter Ended June 30, 2024August 8, 2024 | prnewswire.comPostpartum Depression Drugs Market Size Report 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, TalkspaceAugust 2, 2024 | theglobeandmail.comLipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal StudyJune 25, 2024 | prnewswire.comLipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024June 10, 2024 | prnewswire.com7 Penny Biotech Stocks to Triple Your InvestmentMay 28, 2024 | investorplace.comLPCN Stock Earnings: Lipocine Beats EPS for Q1 2024May 9, 2024 | investorplace.comLipocine Announces Financial Results for the First Quarter Ended March 31, 2024May 9, 2024 | finance.yahoo.comLipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024May 8, 2024 | prnewswire.comLipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154May 1, 2024 | prnewswire.comLipocine hopes obesity drug could boost muscle mass in combo with GLP1-RAsApril 12, 2024 | msn.comLipocine Inc.: Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityApril 11, 2024 | finanznachrichten.deLipocine annonce les résultats positifs d'une étude sur le traitement de l'obésitéApril 11, 2024 | fr.investing.comLipocine Reports Positive Phase 2 Results For LPCN 2401 In Participants With ObesityApril 11, 2024 | markets.businessinsider.comLipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityApril 11, 2024 | finance.yahoo.comLipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityApril 11, 2024 | prnewswire.comLipocine Inc.: Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisMarch 28, 2024 | finanznachrichten.deLipocine: LPCN 1148 Meets Primary And Hepatic Encephalopathy Endpoints In Phase 2 StudyMarch 28, 2024 | markets.businessinsider.comLipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisMarch 28, 2024 | prnewswire.comCirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsightMarch 25, 2024 | finance.yahoo.comLipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154March 25, 2024 | prnewswire.comLPCN Stock Earnings: Lipocine Beats EPS for Q4 2023March 7, 2024 | investorplace.comLipocine GAAP EPS of -$3.14March 7, 2024 | seekingalpha.comLipocine Announces Financial Results for the Full Year Ended December 31, 2023March 7, 2024 | prnewswire.comLipocine to Present at 36th Annual Roth ConferenceMarch 6, 2024 | finance.yahoo.comLipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154February 6, 2024 | finance.yahoo.comLipocine Inc.: Lipocine Announces Continued Commercialization of TLANDO through Verity PharmaceuticalsFebruary 2, 2024 | finanznachrichten.deLipocine transfère la commercialisation de TLANDO à Verity PharmaFebruary 2, 2024 | fr.investing.comLipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsFebruary 2, 2024 | finance.yahoo.com Get Lipocine News Delivered to You Automatically Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter. Email Address LPCN Media Mentions By Week LPCN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LPCN News Sentiment▼0.000.63▲Average Medical News Sentiment LPCN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LPCN Articles This Week▼20▲LPCN Articles Average Week Get Lipocine News Delivered to You Automatically Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DBVT News ORMP News ALXO News VOR News ADVM News COYA News MNOV News PYXS News PWUP News INZY News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LPCN) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipocine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LPCN Stock Alerts